Can a weight-loss shot help your heart?
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors gave a medicine called semaglutide to obese people to help them lose weight and improve their health.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 545 / 72
Evidence Score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors gave a medicine called semaglutide to obese people to help them lose weight and improve their health.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 545 / 72
Evidence Score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Publication
Authors
Ghusn W, Fansa S, Anazco D, Tama E, Nicolalde B, Gala K, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feres F, Hurtado MD, Acosta A
Related Content
Claims (6)
In people who are overweight or obese but do not have diabetes, the medication semaglutide lowers the risk of serious heart-related events such as heart attack or stroke, and this benefit occurs even when some of the effect is not due to weight loss.
In adults with obesity taking semaglutide for 12 months, measurable improvements were seen in blood sugar, cholesterol, blood pressure, liver enzymes, and cardiovascular risk indicators.
In a group of adults with obesity who were given the medication semaglutide, 64% lost at least 10% of their body weight and 41% lost at least 15% after one year of treatment.
In adults with obesity who took weekly semaglutide for one year, most lost at least 5% of their body weight, with many losing 10% or more, and a smaller group losing 20% or more.
Among adults with obesity taking semaglutide for a year, those without type 2 diabetes lost an average of 16.9% of their body weight, while those with type 2 diabetes lost an average of 9.9%.